It was noticeable within the first 6-8 weeks, honestly. By month 2 I was seeing readings in the low 120s/high 70s consistently, which was lower than I'd been in years even on medications. My PCP said the early improvement likely reflects both the natriuretic effect and reduced caloric intake affecting fluid balance.
But the real BP improvements correlated with substantial weight loss. The biggest drops came between months 2-6 when I was losing the most weight. After that it stabilized.
For context, here's what the aggregate trial data shows for BP reduction with semaglutide 2.4 mg:
| Trial | Population | SBP Reduction (vs. placebo) | Weight Loss |
|---|---|---|---|
| STEP 1 | Obesity, no T2DM | -5.1 mmHg | -12.4% |
| STEP 2 | Obesity + T2DM | -3.6 mmHg | -9.6% |
| STEP 3 | Obesity + IBT | -5.6 mmHg | -16.0% |
| SELECT | Obesity + CVD | -3.4 mmHg | -9.4% |
These are mean population-level effects. Individual responses can be much more dramatic, especially in patients with higher baseline BP. The OP's result is exceptional but not unheard of in clinical practice.
Great discussion. I want to flag something important for members reading this: never stop or reduce blood pressure medications on your own. The OP did this under close medical supervision with a planned de-escalation protocol. Abruptly stopping BP meds can cause rebound hypertension, which carries real risk.
If you're experiencing lower BP readings on GLP-1 therapy, bring those readings to your physician and let them guide the medication adjustment. Safety first.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemEchoing the mod's comment. I'll add that the patients who benefit the most from BP medication reduction on GLP-1 therapy tend to be those whose hypertension was primarily driven by obesity, insulin resistance, and volume overload — rather than primary/essential hypertension with strong genetic components.
If your hypertension was diagnosed at a normal BMI with a strong family history, don't expect the same degree of de-escalation. The etiology matters enormously.
For patients with obesity-related hypertension, however, GLP-1 RA therapy combined with weight loss can genuinely be transformative. I've had patients come off 3-4 medications. It's remarkable and, in my 20 years of practice, unprecedented for any single intervention to achieve this so consistently.